Skip to main content
. Author manuscript; available in PMC: 2019 Jun 15.
Published in final edited form as: Thromb Haemost. 2015 Jun 11;114(4):735–747. doi: 10.1160/TH14-11-0907

Figure 5. VEGF-A silencing in MSCpotential abolishes treprostinil-mediated vasculogenic.

Figure 5.

Experiments were performed with 3×106 cells per implant. ECFC and transfected MSC were suspended in 200 μL of Matrigel and injected subcutaneously on the back of 6- to 7-week-old male athymic nu/nu mice.

A- ECFC co-implanted with transfected MSC (si control all-star negative control from Qiagen® or siVEGF-A from Santa Cruz Biotechnologies®) with or without treprostinil. Representative photographs of Matrigel explants at day 10 after injection

B- ECFC co-implanted with transfected MSC with or without treprostinil. Representative photographs of histological sections stained with H&E. Scale bar = 50 μm

C- Quantification of microvessel density as microvessels/mm2. Data are mean ± SEM.